Adenovirus vector-based vaccines for human immunodeficiency virus type 1

Area of Science:

• Virology and Immunology
• Gene Therapy and Vaccine Development

Background:

• Recombinant adenovirus (rAd) vectors are efficient for gene delivery but trigger potent immune responses, limiting their use in gene therapy.
• The immunogenicity of rAd vectors, a drawback for gene therapy, is advantageous for vaccine development.

Purpose of the Study:

• To review the progress in developing recombinant adenovirus vector-based vaccines.
• To focus on the application of rAd vaccines for human immunodeficiency virus type 1 (HIV-1).

Main Methods:

• Review of existing literature on recombinant adenovirus vector applications in vaccines.
• Analysis of immunogenicity and protective efficacy data from animal models.
• Examination of early-phase clinical trial data for rAd vaccines.

Main Results:

• Recombinant adenovirus vectors have demonstrated significant immunogenicity and protective efficacy in various animal models.
• Numerous rAd vaccines targeting different pathogens are progressing through early-phase clinical trials.

Conclusions:

• Recombinant adenovirus vectors are a viable platform for vaccine development, leveraging their inherent immunogenicity.
• Further development and clinical trials are crucial for advancing rAd vector-based vaccines, especially for challenging targets like HIV-1.